BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matsuoka T, Yashiro M. Precision medicine for gastrointestinal cancer: Recent progress and future perspective. World J Gastrointest Oncol 2020; 12(1): 1-20 [PMID: 31966910 DOI: 10.4251/wjgo.v12.i1.1] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Kasi PM, Sawyer S, Guilford J, Munro M, Ellers S, Wulff J, Hook N, Krinshpun S, Koyen Malashevich A, Malhotra M, Rodriguez A, Moshkevich S, Grothey A, Kopetz S, Billings P, Aleshin A. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. BMJ Open 2021;11:e047831. [PMID: 34561256 DOI: 10.1136/bmjopen-2020-047831] [Reference Citation Analysis]
2 Ghidini M. New Tools for Precision and Personalized Treatment in Gastrointestinal Cancers. GastrointestDisord 2021;3:204-6. [DOI: 10.3390/gidisord3040019] [Reference Citation Analysis]
3 Amintas S, Dupin C, Boutin J, Beaumont P, Moreau-Gaudry F, Bedel A, Krisa S, Vendrely V, Dabernat S. Bioactive food components for colorectal cancer prevention and treatment: A good match. Crit Rev Food Sci Nutr 2022;:1-15. [PMID: 35128990 DOI: 10.1080/10408398.2022.2036095] [Reference Citation Analysis]
4 Salati M, Venetis K, Fassan M, Malapelle U, Pagni F, Sajjadi E, Fusco N, Ghidini M. ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality. Future Oncol 2021;17:4607-18. [PMID: 34406032 DOI: 10.2217/fon-2021-0228] [Reference Citation Analysis]
5 Hu R, Bi R, Jiang L, Yang X, Zhong Y, Xie X. LncRNA TUSC8 suppresses the proliferation and migration of esophageal cancer cells by downregulation of VEGFA. J Cancer 2021;12:6393-400. [PMID: 34659529 DOI: 10.7150/jca.57814] [Reference Citation Analysis]
6 Pessoa LS, Heringer M, Ferrer VP. ctDNA as a cancer biomarker: A broad overview. Crit Rev Oncol Hematol. 2020;155:103109. [PMID: 33049662 DOI: 10.1016/j.critrevonc.2020.103109] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
7 Songjang W, Nensat C, Pongcharoen S, Jiraviriyakul A. The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review). Biomed Rep 2021;15:86. [PMID: 34512974 DOI: 10.3892/br.2021.1462] [Reference Citation Analysis]
8 Singla P, Musyuni P, Aggarwal G, Singh H. Precision Medicine: An Emerging Paradigm for Improved Diagnosis and Safe Therapy in Pediatric Oncology. Cureus 2021;13:e16489. [PMID: 34430104 DOI: 10.7759/cureus.16489] [Reference Citation Analysis]
9 Yamamoto H, Watanabe Y, Sato Y, Maehata T, Itoh F. Non-Invasive Early Molecular Detection of Gastric Cancers. Cancers (Basel) 2020;12:E2880. [PMID: 33036473 DOI: 10.3390/cancers12102880] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
10 Yashiro M, Kuroda K, Masuda G, Okuno T, Miki Y, Yamamoto Y, Sera T, Sugimoto A, Kushiyama S, Nishimura S, Togano S, Ohira M. Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer. Sci Rep 2021;11:4698. [PMID: 33633310 DOI: 10.1038/s41598-021-84107-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Woodhouse R, Li M, Hughes J, Delfosse D, Skoletsky J, Ma P, Meng W, Dewal N, Milbury C, Clark T, Donahue A, Stover D, Kennedy M, Dacpano-Komansky J, Burns C, Vietz C, Alexander B, Hegde P, Dennis L. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS One 2020;15:e0237802. [PMID: 32976510 DOI: 10.1371/journal.pone.0237802] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]